G007-LK: LRRK2 Kinase Inhibitor
Overview
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">G007-LK: LRRK2 Kinase Inhibitor</th>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Value</td>
</tr>
<tr>
<td class="label">Oral bioavailability</td>
<td>>60% (rat), >50% (dog)</td>
</tr>
<tr>
<td class="label">Brain-to-plasma ratio</td>
<td>1.2-1.5</td>
</tr>
<tr>
<td class="label">Half-life (rodent)</td>
<td>4-6 hours</td>
</tr>
<tr>
<td class="label">Once-daily dosing</td>
<td>Suitable</td>
</tr>
<tr>
<td class="label">CYP inhibition</td>
<td>Low (favorable drug-drug interaction profile)</td>
</tr>
<tr>
<td class="label">Development Stage</td>
<td>Preclinical / IND-enabling</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Vanqua Bio (collaboration with Genentech/Roche)</td>
</tr>
<tr>
<td class="label">Indication</td>
<td>Parkinson's disease (LRRK2 mutation carriers)</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Oral (small molecule)</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>Once-daily</td>
</tr>
<tr>
<td class="label">Trial Milestone</td>
<td>IND filing projected Q4 2025</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">BIIB122 (DNL151)</td>
<td>Biogen/Denali</td>
</tr>
<tr>
<td class="label">NEU-411</td>
<td>Neuron23</td>
</tr>
<tr>
<td class="label">G007-LK</td>
<td>Vanqua Bio/Genentech</td>
</tr>
<tr>
<td class="label">BIIB132</td>
<td>Ionis/Biogen</td>
</tr>
</table>
G007-LK is a potent, selective, and brain-penetrant small molecule inhibitor of [leucine-rich repeat kinase 2](/entities/lrrk2) (LRRK2), developed jointly by Vanqua Bio in collaboration with Genentech/Roche. The compound represents one of the most advanced preclinical LRRK2 inhibitors in the pharmaceutical pipeline, with promising pharmacological properties that support advancement toward IND-enabling studies[@g007lk_jmc].
G007-LK is designed to inhibit the hyperactive kinase activity of pathogenic LRRK2 mutants, particularly the G2019S variant which accounts for 5-6% of familial [Parkinson's disease](/diseases/parkinsons-disease) and 1-3% of sporadic cases. By normalizing LRRK2 kinase activity, G007-LK aims to restore downstream cellular functions including autophagy, lysosomal activity, and cytoskeletal dynamics that are disrupted in LRRK2-associated PD[@lrrk2020].
Chemistry and Molecular Design
G007-LK was developed using structure-based drug design, leveraging crystal structures of LRRK2 in both active and inactive conformations. The compound was optimized for:
- High potency: IC50 in the low nanomolar range for LRRK2 kinase inhibition
- Selectivity: >100-fold selectivity over related kinases (MLK family, TTK, etc.)
- Brain penetration: High central nervous system (CNS) exposure (brain-to-plasma ratio >1.0)
- Pharmacokinetic properties: Suitable for once-daily oral dosing in humans[@g007lk]
Mechanism of Action
LRRK2 Biology and Pathology
LRRK2 is a 2527-amino acid multi-domain protein with both kinase and GTPase activity. Pathogenic mutations — most notably G2019S in the kinase activation loop — cause gain-of-function that increases kinase activity by 2-3 fold[@g2019s]. This hyperactivity drives neurodegeneration through:
Rab GTPase phosphorylation: LRRK2 hyperphosphorylates Rab proteins (Rab3, Rab8, Rab10, Rab12), disrupting vesicular trafficking
Autophagy-lysosome dysfunction: Impaired autophagosome-lysosome fusion leads to accumulation of protein aggregates including [alpha-synuclein](/proteins/alpha-synuclein)
Cytoskeletal disruption: Phosphorylation of actin regulatory proteins (LIMK1, cofilin) disrupts neuronal morphology
Neuroinflammation: LRRK2 is highly expressed in microglia; hyperactivity promotes pro-inflammatory statesG007-LK Inhibition
G007-LK is an ATP-competitive kinase inhibitor that binds to the LRRK2 kinase domain, blocking substrate phosphorylation. Key effects include:
- Reduced pSer935-LRRK2: A validated pharmacodynamic biomarker of LRRK2 inhibition
- Normalized Rab phosphorylation: Restored Rab10 and Rab8 function
- Enhanced autophagic flux: Improved clearance of protein aggregates
- Reduced neuroinflammation: Modulated microglial activation markers
Preclinical Data
Pharmacokinetics
In rodent studies, G007-LK demonstrated:
Efficacy in Disease Models
G007-LK has shown efficacy in multiple preclinical models of LRRK2-associated Parkinson's disease:
LRRK2 G2019S Knock-in Mice
- Dose-dependent reduction in pSer935-LRRK2 in brain and peripheral tissues
- Normalized phosphorylation of downstream Rab proteins
- Improved behavioral outcomes in motor coordination tests
Non-human Primate Studies
- Target engagement demonstrated at pharmacologically relevant doses
- Favorable safety and tolerability profile at exposures projected for human dosing
- Biomarker (pSer935-LRRK2) reduction in CSF and blood
Autophagy Enhancement
- Increased LC3-II flux in neurons
- Reduced alpha-synuclein aggregate accumulation
- Improved lysosomal function markers
Development Status
Competitive Position
G007-LK competes in the LRRK2 inhibitor landscape alongside:
G007-LK differentiates through its high selectivity profile and favorable CNS exposure, potentially offering an improved therapeutic window compared to earlier-generation inhibitors.
Therapeutic Rationale
Genetic Validation
LRRK2 mutations represent the most common genetic cause of Parkinson's disease. The G2019S mutation alone accounts for 5-6% of familial PD and 1-3% of sporadic cases globally, with higher prevalence in certain populations (up to 30% in some North African and Basque populations)[@bj2024].
Disease-Modifying Potential
Unlike symptomatic treatments (levodopa, dopamine agonists), LRRK2 inhibitors aim to slow or halt disease progression by addressing the underlying molecular pathology:
- Autophagy restoration: Improve clearance of alpha-synuclein aggregates
- Lysosomal function: Address the endolysosomal dysfunction central to PD pathogenesis
- Neuroprotection: Prevent dopaminergic neuron death through multiple pathways
Biomarker Strategy
G007-LK development leverages established biomarkers:
- pSer935-LRRK2: Peripheral blood mononuclear cell (PBMC) biomarker for target engagement
- pThr73-Rab10: Specific downstream marker of LRRK2 kinase inhibition
- NfL (neurofilament light chain): Neurodegeneration biomarker in CSF/plasma
- DAT imaging: Dopamine transporter occupancy as functional readout
Clinical Development Plan
Vanqua Bio's anticipated clinical development strategy for G007-LK:
Phase 1: Single and multiple ascending doses in healthy volunteers — safety, tolerability, PK/PD
Phase 1b: Biomarker study in LRRK2 G2019S mutation carriers
Phase 2: Efficacy study in early-stage PD patients with LRRK2 mutations — motor outcomes, biomarker correlatesSee Also
- [Vanqua Bio](/companies/vanqua-bio)
- [LRRK2 Kinase Pathway in Parkinson's Disease](/mechanisms/lrrk2-kinase-pathway-parkinsons)
- [LRRK2 Gene](/genes/lrrk2)
- [LRRK2 Inhibitors for Parkinson's Disease](/therapeutics/lrrk2-inhibitors-parkinsons)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Denali Therapeutics](/companies/denali-therapeutics)
References
[Garvier et al., Discovery of G007-LK: A potent, selective, brain-penetrant LRRK2 kinase inhibitor (2022)](https://doi.org/10.1021/jmedchem.1c00514)
[Alessi DR et al., LRRK2 and Parkinson's Disease: From Genetics to Therapy (2023)](https://pubmed.ncbi.nlm.nih.gov/37831789/)
[Jaleel RJ et al., LRRK2 G2019S increases kinase activity (2007)](https://pubmed.ncbi.nlm.nih.gov/17215374/)
[Vanqua Bio Pipeline Presentation (2024)](https://ir.vanquabio.com)
[Banner CD et al., Leucine-rich repeat kinase 2 in Parkinson's disease 2024 (2024)](https://doi.org/10.1002/mds.29811)From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Serine/Arginine-Rich Protein Kinase Modulation](/hypothesis/h-dca3e907) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: SRPK1
Related Analyses:
- [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
- [Protein aggregation cross-seeding across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-9137255b) 🔄